Inhalation Sciences’ in-vitro technology XposeALI® granted patent in China
Inhalation Sciences’ patent application for XposeALI®, the company's unique, proprietary module for aerosol exposure of cells, has been approved in China. The product patent, which includes the design of the product, applies until the end of 2033. Inhalation Sciences’ products are protected by a total of 6 patent families.
Inhalation Sciences (ISAB) develops advanced labtech R&D instruments used to study the effects of inhaled particles on the lungs and wider health. At the centre of the company’s technology is the PreciseInhale® system. A range of modules can be attached to PreciseInhale, depending on users’ research and development goals.
XposeALI® is the company’s proprietary module for the aerosol exposure of cells. The current module is in the early stages of commercialization and is installed at Karolinska Institute in Stockholm.
Fredrik Sjövall, CEO: “The approval of our patent in China is further proof of how innovative our products are. It is a strong basis for future expansion in China.”
For more information about Inhalation Sciences please contact: Fredrik Sjövall, CEO Email: firstname.lastname@example.org Phone: +46 (0)70 64 508 75Press release in PDF format